StockNews.AI
KNSA
StockNews.AI
180 days

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

1. Kiniksa will report Q4 and full year 2024 financial results on Feb 25. 2. A live webcast and conference call are scheduled via the company website. 3. The announcement reiterates the company’s focus on cardiovascular therapies.

Earnings
+1.68%Current Return
VS
-1.72%S&P 500
$19.6902/20 04:22 PM EDTEvent Start
$20.0202/21 10:41 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

The announcement is a routine earnings call notice without unexpected details. Historical earnings announcements tend to cause volatility primarily after results release rather than at the announcement stage.

How important is it?

While earnings calls are critical events, this announcement is routine and expected. It may prompt short-term price movement based on the results, but holds moderate overall impact until details are revealed.

Why Short Term?

Earnings releases generally influence stock price immediately upon announcement of results. This event is expected to have immediate, short-term impacts rather than altering long-term fundamentals.

Related Companies

February 20, 2025 16:01 ET  | Source: Kiniksa Pharmaceuticals, Ltd. LONDON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 25, 2025 at 8:30 a.m. Eastern Time to report its fourth quarter and full year 2024 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event. About KiniksaKiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio assets are based on strong biologic rationale or validated mechanisms and offer the potential for differentiation. For more information, please visit www.kiniksa.com. Every Second Counts! ® Kiniksa Investor ContactJonathan Kirshenbaum(781) 829-3949jkirshenbaum@kiniksa.com Kiniksa Media ContactTyler Gagnon (781) 431-9100tgagnon@kiniksa.com

Related News